CD4+CD25+ regulatory T cells in tumor immunity
Autor: | Ting Zhou, Xiu-Qing Lin, Xin Chen, Yong Du, ZhiMing Huang, Yan Qian |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
CD4-Positive T-Lymphocytes Immunology chemical and pharmacologic phenomena Biology T-Lymphocytes Regulatory Immune tolerance 03 medical and health sciences 0302 clinical medicine Immune system Immunity Antigens Neoplasm Neoplasms Immunology and Allergy Cytotoxic T cell Animals Humans IL-2 receptor Pharmacology Interleukin-2 Receptor alpha Subunit FOXP3 Peripheral tolerance hemic and immune systems Forkhead Transcription Factors 030104 developmental biology CTLA-4 030215 immunology |
Zdroj: | International immunopharmacology. 34 |
ISSN: | 1878-1705 |
Popis: | Regulatory T cells (Tregs) are essential for maintaining peripheral tolerance, preventing autoimmune diseases and limiting chronic inflammatory diseases. Depletion of Tregs results in the onset of a variety of autoimmune diseases. Tregs are defined based on expression of CD4, CD25, and the transcription factor, FoxP3. It is now clear that three inhibitory cytokines, IL-10, IL-35 and TGF-β, are key mediators of Tregs function. Tregs have been shown to be important contributors to the development of immune tolerance toward tumors and play a critical role in the induction of tolerance to tumor associated antigens and suppression of anti-tumor immunity. Increasing researches support the existence of elevated numbers of regulatory T cells in cancer patients. Poor prognosis and decreased survival rates are closely correlated with higher Treg cell frequencies. Depletion of Tregs or blockade of their immune inhibitory role can enhance anti-tumor effects. Recent evidence suggests that Tregs may be responsible for the failure of host anti-tumor immunity by suppressing cytotoxic T-cells. In this review, we discuss cellular and molecular mechanisms in the differentiation and function of Tregs in tumor immunity. |
Databáze: | OpenAIRE |
Externí odkaz: |